What Makes Intellia Therapeutics (NTLA) an Interesting Investment?

Group 1 - Contrarius Global Equity Fund achieved a return of 30.9% in the September quarter, significantly outperforming the benchmark MSCI World Index at 7.3% and the Average Global Equity Fund at 5.5% [1] - The fund's investment strategy is independent of benchmark considerations, leading to portfolios that typically deviate from the benchmark World Index [1] - The fund highlighted its top five holdings, indicating its leading picks for 2025 [1] Group 2 - Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage gene editing company with a one-month return of 12.84% but a 52-week loss of 21.61% [2] - As of December 29, 2025, Intellia Therapeutics, Inc. had a stock price of $9.14 per share and a market capitalization of $1.059 billion [2] - The treatment process for Intellia's Casgevy involves extracting stem cells, editing them, and administering a high dose of chemotherapy, which is physically demanding and costly, but the potential benefits outweigh the drawbacks [3]